Experimental Psilocybin Trial in Alzheimer’s Patient Shows Temporary Cognitive and Memory Improvements
A new experimental study has drawn attention after an 80-year-old woman with advanced Alzheimer’s disease showed temporary improvements in speech, memory recall, and emotional responsiveness following treatment with psilocybin, the psychoactive compound found in psychedelic mushrooms.
The patient, who had experienced severe cognitive decline and required full-time care, was enrolled in a research study published in Frontiers in Neuroscience. At baseline, she could communicate only in limited sounds, had lost significant motor control, and required assistance with basic daily functions. Researchers administered a high-dose psilocybin session under controlled conditions as part of an exploratory investigation into its neurological effects.
Following the treatment, the study reports that the patient exhibited a striking temporary shift in behavior and cognition. Hours after the session, she began engaging in extended autobiographical speech, demonstrating increased emotional expression, improved social interaction, and moments of apparent memory recall. Caregivers also observed short-term improvements in mobility, communication, and continence over the following days and weeks.
Researchers emphasize that the findings are highly preliminary and based on a single case, meaning no broad conclusions can be drawn about effectiveness. While the results raise questions about whether some cognitive pathways in advanced Alzheimer’s disease may remain partially accessible, experts caution that the condition continued to progress and the improvements were not sustained, underscoring that psilocybin is not a cure.
